Skip to content

Study · Animal study (in vivo) · mouse and rat · 1999

6 results

Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.

Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, Egan JM

Diabetologia1 Jan 1999Cited by 150 (Europe PMC)

PMID10027577 (opens in a new tab)DOI10.1007/s001250051111 (opens in a new tab)PepBankPUB-10027577
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In rats, intravenous exendin‑4 had greater insulinotropic potency than glucagon-like peptide-1.

    In plain wordsIn rats, exendin‑4 stimulated insulin release more potently than glucagon-like peptide-1.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulinotropic potency
    Study

    ratn: not reported in source

    Comparator
    glucagon-like peptide-1
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Measurements

    ED50
    0.0143 nmol/kg
    exendin-4

    Source sentences

    Summary
    We report that exendin-4 is a more potent insulinotropic agent when given intravenously to rats than is glucagon-like peptide-1 (ED50 0.19 nmol/kg for glucagon-like peptide-1 vs 0.0143 nmol/kg for exendin-4) and causes a greater elevation in cAMP concentrations in isolated islets.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, blood glucose after daily exendin‑4 was 5.0+/-2.6 mmol/l versus diabetic concentrations of 13.2+/-2.8 mmol/l.

    In plain wordsIn mice, blood glucose after daily exendin‑4 was lower than the reported diabetic concentrations.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBlood glucose after 1 week
    Study

    mousen: not reported in source

    diabetic mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intraperitoneal · 1 weekAs given in this study (mouse).

    Measurements

    Blood glucose
    5 mmol/l
    after 1 week

    Source sentences

    Summary
    After 1 week of treatment blood glucoses were 5.0+/-2.6 mmol/l compared to diabetic concentrations of 13.2+/-2.8 mmol/l.
    1 context sentence
    Summary · context
    Of even greater interest we found that when given intraperitoneally only once daily to diabetic mice it had a prolonged effect of lowering blood glucose.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, exendin‑4 reduced HbA1c to 4.7+/-0.25% versus 8.8+/-0.4% in untreated animals.

    In plain wordsIn mice, exendin‑4 lowered HbA1c compared with untreated diabetic mice.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c after 13 weeks
    Study

    mousen: not reported in source

    diabetic mice
    Comparator
    non-treated diabetic animals
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intraperitoneal · 13 weeksAs given in this study (mouse).

    Source sentences

    Summary
    After 13 weeks of daily treatment HbA1c was 8.8+/-0.4% in non-treated diabetic animals compared with 4.7+/-0.25% in treated diabetic animals.
    1 context sentence
    Summary · context
    Of even greater interest we found that when given intraperitoneally only once daily to diabetic mice it had a prolonged effect of lowering blood glucose.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, blood glucose was lower with exendin‑4 than without treatment.

    In plain wordsIn mice, exendin‑4 lowered blood glucose compared with untreated diabetic mice.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBlood glucose in treated animals
    Study

    mousen: not reported in source

    diabetic mice
    Comparator
    non-treated diabetic animals
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intraperitoneal · 13 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Blood glucoses also were lower (p < 0.005) and insulin concentrations higher (p < 0.02) in the treated animals.
    2 context sentences
    Summary · context
    After 13 weeks of daily treatment HbA1c was 8.8+/-0.4% in non-treated diabetic animals compared with 4.7+/-0.25% in treated diabetic animals.
    Summary · context
    Of even greater interest we found that when given intraperitoneally only once daily to diabetic mice it had a prolonged effect of lowering blood glucose.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic mice, insulin concentrations were higher with exendin‑4 than without treatment.

    In plain wordsIn mice, exendin‑4 increased insulin concentrations compared with untreated diabetic mice.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseInsulin concentrations
    Study

    mousen: not reported in source

    diabetic mice
    Comparator
    non-treated diabetic animals
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · intraperitoneal · 13 weeksAs given in this study (mouse).

    Source sentences

    Summary
    Blood glucoses also were lower (p < 0.005) and insulin concentrations higher (p < 0.02) in the treated animals.
    2 context sentences
    Summary · context
    After 13 weeks of daily treatment HbA1c was 8.8+/-0.4% in non-treated diabetic animals compared with 4.7+/-0.25% in treated diabetic animals.
    Summary · context
    Of even greater interest we found that when given intraperitoneally only once daily to diabetic mice it had a prolonged effect of lowering blood glucose.
  6. 06LabEx vivo tissueActivity measurement

    In isolated islets, exendin‑4 increased cAMP concentrations more than glucagon-like peptide-1.

    In plain wordsIn lab tests, exendin‑4 increased islet cAMP more than glucagon-like peptide-1.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasecAMP concentrations
    Study

    n: not reported in source

    isolated islets
    Comparator
    glucagon-like peptide-1
    Outcome group
    Receptor activity and mechanism · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    We report that exendin-4 is a more potent insulinotropic agent when given intravenously to rats than is glucagon-like peptide-1 (ED50 0.19 nmol/kg for glucagon-like peptide-1 vs 0.0143 nmol/kg for exendin-4) and causes a greater elevation in cAMP concentrations in isolated islets.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2/3Results postedNCT00650546

Role of Exenatide in NASH-a Pilot Study

Indiana Universityn = 8Aug 2006 to Aug 2010

Nonalcoholic Fatty Liver Disease

Trial pageClinicalTrials.govUpdated 11 Apr 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.